Feasibility and safety of remdesivir in SARS-CoV2 infected renal transplant recipients: A retrospective cohort from a developing nation.

Hari S MeshramVivek B KuteHimanshu PatelSubho BanerjeeVijay NavadiyaSudeep DesaiSyed J RizviVineet MishraSanshriti Chauhan

Published in: Transplant infectious disease : an official journal of the Transplantation Society (2021)

RDV therapy is safe and clinically feasible in renal transplant recipients as seen in our cohort. Larger clinical registries and randomized clinical trials should be conducted to further explore the efficacy in transplant recipients.

Keyphrases

sars cov
respiratory syndrome coronavirus
clinical trial
stem cells
bone marrow
replacement therapy
double blind